Investors should monitor the Q3 2026 topline data from the LEVEL trial as a key catalyst; while near-term fundamentals are deteriorating due to rising losses, the strong cash position and progression of registrational trials support long-term optionality.
Price Chart
Executive Summary
Tenax Therapeutics reported financial results for 2025, highlighted by a significant increase in R&D and G&A expenses leading to a larger net loss, while maintaining a strong cash position of $97.6 million. The company achieved full patient randomization in its Phase 3 LEVEL trial for TNX-103 in PH-HFpEF, with topline data expected in Q3 2026, and initiated the global LEVEL-2 trial. Despite rising losses, the cash runway is expected to fund operations through 2027.
Key Financial Metrics
Key Facts
- Achieved randomization of 230 patients in the Phase 3 LEVEL study; topline data expected Q3 2026
- Initiated global Phase 3 LEVEL-2 trial and opened long-term open-label extension (OLE) study
- Cash and cash equivalents: $97.6 million as of December 31, 2025, sufficient to fund operations through 2027
- R&D expenses increased to $32.7 million in 2025 from $12.7 million in 2024
- G&A expenses rose to $23.7 million in 2025 from $6.8 million in 2024
- Net loss for 2025 was $52.6 million vs. $17.6 million in 2024
- U.S. patent allowance expanded to cover subcutaneous levosimendan formulations across multiple indications
Financial Impact
Net loss tripled to $52.6 million in 2025, driven by higher R&D and G&A spending, but cash position remains strong at $97.6M
Risk Factors
- Clinical trial results may not meet endpoints, leading to potential stock decline
- High burn rate could pressure future financing needs if development timelines extend
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252611 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $1.62 | awaiting T+5 | — | $1.72 (+6.17%) |
Oct 15, 2026 12d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.72 (+26.47%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.72 (+7.50%) |
Oct 9, 2026 18d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.72 (−6.01%) |
Oct 8, 2026 19d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.72 (−8.02%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.72 (−9.47%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.72 (−19.25%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.72 (−6.52%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers